Benjamin Hohl - 04 Apr 2023 Form 4 Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role
Chief Financial Officer
Signature
/s/ Ben Hohl
Issuer symbol
ELVN
Transactions as of
04 Apr 2023
Net transactions value
$0
Form type
4
Filing time
06 Apr 2023, 20:32:51 UTC
Previous filing
27 Feb 2023
Next filing
27 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELVN Stock Option (right to buy) Award $0 +206,000 $0.000000 206,000 04 Apr 2023 Common Stock 206,000 $22.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/4th of the shares subject to the option will vest on February 23, 2024 and 1/48th of the shares subject to the option will vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date